logo

For the Inventor, By the Inventor

Holzkirchen, Germany

Hexal Ag


USPTO Granted Patents = 47

% Expired Patents = 42.6



Forward Citations = 553

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Karin Klokkers (16 out of 19 patents)

silverMedal Wilfried Fischer (14 out of 18 patents)

bronzeMedal Ralf Kibele (5 out of 12 patents)

4.  Andreas Krekeler (5 out of 6 patents)

5.  Anna Sendl-Lang (5 out of 5 patents)

6.  Daniel Bracher (4 out of 4 patents)

7.  Brigitte Freudensprung (3 out of 3 patents)

8.  Dimitri Neumann (2 out of 2 patents)

9.  Michael Sedlmayr (2 out of 3 patents)

10.  Jörg Nink (2 out of 2 patents)

11.  Thomas Kohr (2 out of 2 patents)

12.  Peter Skufca (2 out of 4 patents)

13.  Theresa Taeubrich (2 out of 2 patents)

14.  Patrick Rother (2 out of 2 patents)

15.  Cornelia Beier (2 out of 2 patents)


Core Competencies:
Benzothiophene Compounds
Crystalline Brexpiprazole
Antibody Preparation
Orodispersible Film
Transdermal Therapeutic Systems
Pharmaceutical Compositions
Sustained-Release Formulations
Taste Masking Agents
Controlled-Release Preparations
Pharmaceutical Statin Composition
Micronized Crystalline Compounds
Pharmaceutical Antacids

47 patents:

1. 11123300 - Immediate release tablet of a benzothiophene compound (2021-09-21),
2. 11072605 - Crystalline brexpiprazole (2021-07-27),
3. 11021530 - Antibody preparation (2021-06-01),
4. 10732162 - Method and device for determining the disintegration time of film-shaped pharmaceutical dosage forms (2020-08-04),
5. 10668073 - Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof (2020-06-02),
6. 10548848 - Alogliptin formulation (2020-02-04),
7. 10501450 - Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations (2019-12-10),
8. 10485799 - Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix (2019-11-26),
9. 10335443 - Orodispersible film (2019-07-02),
10. 9895497 - Method for reducing leachables and extractables in syringes (2018-02-20),
11. 9844515 - Transdermal therapeutic system comprising buprenorphine (2017-12-19),
12. 9789112 - Oral pharmaceutical film formulation for bitter tasting drugs (2017-10-17),
13. 9717707 - Pharmaceutical statin composition (2017-08-01),
14. 9592296 - Pharmaceutical composition for oral administration with a statin (2017-03-14),
15. 9480743 - Pharmaceutical formulation comprising a biopharmaceutical drug (2016-11-01),
Hexal AG is a leading pharmaceutical company based in Germany. With a focus on generic drugs, Hexal develops, manufactures, and distributes high-quality and affordable medications to patients worldwide. Our commitment to innovation and patient well-being drives us to constantly improve our products and services. Visit our website to learn more about Hexal's range of generic pharmaceuticals and our dedication to improving global healthcare.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Hexal Ag
47 Patents

#1 in Holzkirchen

#1,120 in Germany

#14,776 in the World

Holzkirchen, DE
Holzkirchen, Germany

Hexal Ag

Forward Citations = 553

59 inventors:

goldMedal Karin Klokkers (16 out of 19 patents)

silverMedal Wilfried Fischer (14 out of 18 patents)

bronzeMedal Ralf Kibele (5 out of 12 patents)

4.  Andreas Krekeler (5 out of 6 patents)

5.  Anna Sendl-Lang (5 out of 5 patents)

Please report any incorrect information to [email protected]
Loading…